Question Is state cannabis legalization or commercialization associated with increased rates of psychosis-related health care claims?
Findings In this cohort study of claims data from 63 680 589 beneficiaries from 2003 to 2017, there was no statistically significant difference in the rates of psychosis-related diagnoses or prescribed antipsychotics in states with medical or recreational cannabis policies compared with states with no such policy.
Meaning The findings of this study do not support an association between state policies legalizing cannabis and psychosis-related outcomes; further research into this topic may be informative.
